Phaseline

Targets › BRADYKININ

BRADYKININ: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Immunology.

Open in Phaseline: the race on BRADYKININ, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute for Asthma and AllergyDeucrictibant XR tablet
Bradykinin B2 receptor antagonist
BRADYKININPhase 1Hereditary Angioedema (HAE)–

Conditions

Hereditary Angioedema (HAE) (2)

Modalities

small molecule (1)

Companies

Institute for Asthma and Allergy (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.